Doug Cole

Doug Cole

General Partner

Doug Cole joined Flagship in 2001 where he focuses on Life Science investments. He came to Flagship with significant industry experience and a strong academic background. Doug holds an AB magna cum laude with High Distinction in English from Dartmouth College, where he was a Senior Fellow and a member of Phi Beta Kappa, and an MD from the University of Pennsylvania School of Medicine, where he was a member of Alpha Omega Alpha. He obtained post-graduate training in medicine at the Johns Hopkins Hospital in Baltimore, MD and in neurology at the Massachusetts General Hospital in Boston, MA. In 1992, Doug was appointed Instructor in Neurology at Harvard Medical School and an Assistant in Neurology at the Massachusetts General Hospital. He established a research program investigating the mechanistic basis of neuronal signaling events and plasticity in neuro-psychiatric disorders with the support of the NIH and several non-profit research foundations.

In 1996, Doug joined Cytotherapeutics, in Providence, RI. As Medical Director, he oversaw various research and clinical activities related to the company’s cell-based therapeutic technologies. In 1997, he was appointed Program Executive at Vertex Pharmaceuticals, Inc., in Cambridge, MA, where he led a multidisciplinary program that conducted preclinical development through Phase II studies in tissue protection and repair, oversaw an international research collaboration, and was responsible for identifying strategic market and technology opportunities in multiple arenas.

At Flagship, Doug has led investments in CombinatoRx, Tetraphase Pharmaceuticals, Alvine Pharmaceuticals, Concert Pharmaceuticals, Quanterix Corporation, Receptos, Agios Pharmaceuticals, Seventh Sense Biosystems, and Avedro. He is a co-founder of Flagship portfolio company Ensemble Therapeutics, Permeon Biologics, and Moderna Therapeutics. He currently serves on the Board of Directors of Tetraphase Pharmaceuticals, Quanterix Corporation, Receptos, Agios, Selecta Biosciences and Avedro.  He formerly served on the Board of Directors of AVEO Pharmaceuticals (NASDAQ: AVEO), CombinatoRx, CGI and Morphotek.

Doug is a member of the Scientific Advisory Board of the Spinal Muscular Atrophy Foundation, the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics, the Scientific Advisory Board of the Massachusetts Life Sciences Center, and serves on the Board of Directors of the Birch Rock Camp in Waterford, ME.

Current Investments

  • Agios Pharmaceuticals, Inc.
  • Avedro, Inc.
  • Concert Pharmaceuticals, Inc.
  • Editas Medicine
  • Ensemble Therapeutics Corporation
  • Permeon Biologics Inc.
  • Quanterix Corporation
  • Receptos, Inc.
  • Syros Pharmaceuticals
  • moderna